April 3, 2018

PerkinElmer to Highlight Innovative Cancer Research Technologies at 2018 AACR Annual Meeting

Solutions Enable Scientists to Advance Understanding of Cancer -- from Concept through Translation

WHAT: [PerkinElmer, Inc.](), a global leader committed to innovating for a healthier world, today announced that it will showcase its comprehensive portfolio of solutions for cancer research professionals at the [American Association of Cancer Research (AACR) Annual Meeting 2018](). AACR brings together life sciences professionals to drive cancer science to patient care.

WHEN: April 14-18, 2018

WHERE: McCormick Place North/South
Chicago, Illinois
Booth #2612

WHY: Certain research related to immuno-oncology, epigenetics, and kinase-related growth factors has resulted in new, more effective cancer treatments.   Critical to achieving a better understanding of cancer and all its complexities are the latest advancements in, cancer biomarker detection, imaging, and analysis , regardless of the laboratory or research environment.

HOW: PerkinElmer's solutions enable researchers to understand cancer in its microenvironment by imaging and analyzing tissue samples to identify disease subtypes and validate targets. They can leverage PerkinElmer's in vivo imaging systems and reagents to see how tumors respond to treatments in animal models from molecular, functional, and anatomical perspectives.

PerkinElmer's high content screening and informatics offerings enable phenotypic analysis of cancer cells. Scientists can also conduct cancer biomarker detection and mechanism of action studies with PerkinElmer's multimode plate readers, assays and reagents.

"Our DNA/RNA, cell imaging, in vivo imaging, and tissue imaging solutions combine to empower cancer researchers with the critical tools they need for faster, more targeted breakthroughs," said Jim Corbett, Executive Vice President and President, Discovery & Analytical Solutions, PerkinElmer. "By automating cancer analysis workflows with our technologies, scientists can be more productive and gain unique insights that can translate into better therapeutic options."

ON DISPLAY: PerkinElmer will display a broad range of offerings at AACR 2018, including:

DNA/RNA Solutions

- **JANUS® G3R NGS Express Workstation:** uses an intuitive library-prep interface for fragment library preparation, amplicon sequencing, target capture, and sample normalization.

- **Sciclone G3 NGSx Workstation:** a complete, high throughput workstation for library prep, sequence capture, and normalization. The system offers more than 75 optimized methods for library prep and allows users to prep samples for up to 480 libraries or 192 exome captures per week, with the flexibility to handle up to 96 samples per run

- **VICTOR® Nivo™ Multimode Microplate Reader:** with a compact footprint and light-weight design, this system offers high performance detection modes and easy-to-use software, enabling scientists to accelerate biochemical and cell-based assays for disease research and drug development. The VICTOR Nivo reader features a wide range of key detection modes, top and bottom reading for all modes and space for up to 32 filters to accommodate multiple users and applications.

- **chemagic™ 360® instrument:** a high-throughput benchtop solution for DNA/RNA isolation from human samples which represents a top quality sample preparation system. This instrument leverages PerkinElmer's many years of experience in automated, magnetic bead based nucleic acid isolation, delivering high yield and purity DNA/RNA that are integral to the success of downstream applications.

Cellular Imaging

- **Opera® Phenix™ High-Content Screening System:** combines speed and sensitivity for high-throughput, phenotypic screening and assays involving complex disease models, such as live cells, primary cells and microtissues.

- **EnSight® Multimode Plate Reader:** a benchtop system that offers well imaging, label-free and labelled detection technologies, enabling researchers to compare and combine results from orthogonal assays using a range of

technologies to make new findings on a single, flexible and upgradeable system.

In Vivo Imaging

- **IVIS® Spectrum™ In Vivo Imaging System** and Comprehensive Suite of *In Vivo* **Imaging Reagents:** help researchers achieve simultaneous molecular and anatomical longitudinal studies for insight into complex biological systems in small animal models. The system contains a comprehensive suite of fluorescent and bioluminescent imaging agents and uses integrated optical and microCT technology, 3D optical tomography and sensitive detection technology.

- **G8 PET/CT Preclinical Imaging System:** an ultra-sensitive and fast multimodal preclinical PET/CT imaging system in a benchtop format, this system enables researchers to image trace amounts of a probe (about 10x lower dose than conventional scanners), reducing barriers to PET imaging, exposure to subjects and researchers, and overall costs.

- **IVIS® Lumina™ X5 Imaging System:** high throughput benchtop 2D optical *in vivo* imaging system that leverages hardware and software advances and smart accessory design. The system provides researchers a streamlined workflow to expedite the understanding of disease progression and to help develop treatments for a wide range of cancers, infectious diseases and other disorders. The multimodal IVIS Lumina X5 provides high-sensitivity, high-throughput bioluminescence and fluorescence imaging with spectral un-mixing. It integrates high-resolution X-ray imaging, allowing scientists to explore multiple facets of a disease by providing both molecular and highly detailed anatomical information in a single image.

Tissue Imaging

- **Vectra Polaris Automated Quantitative Pathology Imaging System:** integrates high throughput, seven color multi-spectral imaging with whole slide scanning in a user-friendly digital pathology workflow to empower immuno-oncology researchers to identify and characterize multiple cell phenotypes simultaneously. Launched in January 2017, the Vectra Polaris system is the latest addition to PerkinElmer's end-to-end Phenoptics™ workflow solutions, which enable immuno-oncology researchers to explore the interaction between tumors and immune cells to obtain a deeper understanding of disease mechanisms and the tumor microenvironment. This can help to unlock the potential for discovering new predictive biomarkers.

- **Mantra™ Quantitative Pathology Workstation:** incorporates multispectral imaging technology, novel image acquisition and inForm® analysis software in an integrated and compact manual workstation to help detect and measure multiple expressed and overlapping biomarkers within a single IHC

or IF tissue section. This workstation enables easy visualization, quantification and phenotyping of multiple types of immune cells.

Kits and Reagents
- **Oncology Research and Drug Discovery:** a wide range of oncology, inflammation and immuno-oncology target options in multiple homogeneous assay formats, including AlphaLISA®, LANCE® TR-FRET, AlphaLISA *SureFire® Ultra™*, Alpha *SureFire Ultra* Multiplex and AlphaPlex®.

Informatics
- **Signals Screening** Researchers need a suitable data management system to transform high content screening analyses into robust biological conclusions. What if all the results, from raw image data, image analysis results, secondary analysis, hit stratification, metadata, and phenotype can be stored in a central location while being able to perform searches, conduct advanced analytics, share data, and collaborate around results? The platform easily integrates screening assay data and phenotypic data and enables scientists to integrate, search, and retrieve relevant data from across internal and external sources. Supporting collaboration and enabling scientists with direct access to all relevant data increases the speed and efficiency of drug discovery and helps to better match patients with effective drugs to improve human health**.**

- **Signals Translational :** PerkinElmer Signals Translational is a software platform that addresses the full translational research workflow with a focus on oncology. The platform enables end users aggregate, search, and analyze data from a wide variety of sources. Connectors for SEND, SDTM, CCLE, and TCGA enables simple integration with public data sources and analysis apps such as Survival Analysis, Batch Effect Detection & Removal, and PCA simplify answering common questions for oncology. PerkinElmer Signals Translational enables your scientists to access relevant data, independently complete complex analyses, and collaborate with colleagues through a common platform that enables biomarker discovery and companion diagnostics development.

- **Signals Medical Review :** To fully ensure patient safety during oncology trials, Medical Monitors require visibility across data sources, CDISC domains, and access to dynamic analyses. Given the elevated safety requirements, monitors can't afford to hunt for specific subjects of interest, rely on manual tracking of the line listing review process, or invest the time to apply generic analytics capabilities. PerkinElmer Signals Medical Review provides a curated analytics experience for Medical Monitors. By creating unlimited patient cohorts based on therapeutic area and study design, Medical Monitors can now quickly find and act on data insights with intuitive, role-specific workflows

MORE: Join the conversation about AACR by following us on Twitter @PerkinElmer.

ABOUT

PERKINELMER:

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. Our dedicated team of about 11,000 employees worldwide is passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics and discovery and analytical solutions markets. Our innovative detection, imaging, informatics, and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us. The Company reported revenue of approximately $2.3 billion in 2017, serves customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at [www.perkinelmer.com.](http://www.perkinelmer.com)

Media Contact:
Alison Cizowski
+1 617-399-4914
perkinelmerdas@apcoworldwide.com